| ID Source | ID |
|---|---|
| PubMed CID | 12303047 |
| CHEMBL ID | 1330113 |
| SCHEMBL ID | 3617 |
| MeSH ID | M0004140 |
| Synonym |
|---|
| NCGC00180906-01 |
| MLS001332439 |
| smr000875245 |
| MLS001332440 |
| 3697-42-5 |
| chlorhexidine dihydrochloride |
| smr000718621 |
| MLS001304094 , |
| MLS001032084 |
| pharmakon1600-01500177 |
| nsc756679 |
| SCHEMBL3617 |
| CHEMBL1330113 |
| (1e)-2-[6-[[amino-[(e)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;hydrochloride |
| chlorhexidinedihydrochloride |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 3.5481 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 39.8107 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| WRN | Homo sapiens (human) | Potency | 89.1251 | 0.1683 | 31.2583 | 100.0000 | AID651768 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 89.1251 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 28.1838 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3489 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| TDP1 protein | Homo sapiens (human) | Potency | 10.9523 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 12.5893 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| PINK1 | Homo sapiens (human) | Potency | 50.1187 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 11.2202 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 67.9K protein | Vaccinia virus | Potency | 10.6101 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 9.8745 | 0.0126 | 8.1569 | 44.6684 | AID2101; AID2590; AID2671 |
| Parkin | Homo sapiens (human) | Potency | 50.1187 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| IDH1 | Homo sapiens (human) | Potency | 10.3225 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 50.3060 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 50.1187 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 0.6561 | 9.4520 | 25.1189 | AID463254 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| snurportin-1 | Homo sapiens (human) | Potency | 50.3060 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 5.0119 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 11.2202 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.5893 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| geminin | Homo sapiens (human) | Potency | 13.6143 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 28.1838 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 100.0000 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TPA: protein transporter TIM10 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 56.0500 | 0.5800 | 26.5476 | 75.8000 | AID493003; AID504542 |
| TPA: protein transporter TIM23 | Saccharomyces cerevisiae S288C | IC50 (µMol) | 100.0000 | 0.8800 | 10.5036 | 32.9000 | AID504544 |
| hepatocyte nuclear factor 4-alpha isoform 2 | Homo sapiens (human) | IC50 (µMol) | 21.4360 | 1.4170 | 5.0866 | 7.8660 | AID651720 |
| perilipin-5 | Homo sapiens (human) | IC50 (µMol) | 4.9115 | 0.9850 | 3.4565 | 9.4680 | AID651677; AID651733 |
| perilipin-1 | Homo sapiens (human) | IC50 (µMol) | 2.8580 | 0.9250 | 3.3033 | 9.6190 | AID651672 |
| melanocortin receptor 4 | Homo sapiens (human) | IC50 (µMol) | 1.5470 | 1.5470 | 4.3142 | 7.1770 | AID602298 |
| rac GTPase-activating protein 1 isoform a | Homo sapiens (human) | IC50 (µMol) | 42.3300 | 7.3900 | 57.8904 | 301.2400 | AID624330 |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | IC50 (µMol) | 4.9115 | 0.9250 | 3.5828 | 9.6190 | AID651677; AID651733 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein 90 | Candida albicans | EC50 (µMol) | 83.6780 | 0.1200 | 6.4855 | 33.8530 | AID2387; AID2400; AID2423 |
| calcineurin A1, putative | Candida dubliniensis CD36 | EC50 (µMol) | 180.0000 | 4.6630 | 6.3810 | 8.0990 | AID2388 |
| mitogen-activated protein kinase kinase kinase kinase 2 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 15.3350 | 0.6700 | 8.5344 | 26.3600 | AID1895; AID1897 |
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.7890 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| mitogen-activated protein kinase kinase kinase 3 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 30.0000 | 2.6800 | 6.6700 | 11.8600 | AID1896 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.6700 | 0.0054 | 3.2510 | 20.9400 | AID1897 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| CAAX prenyl protease 2 isoform 2 | Homo sapiens (human) | AC50 | 12.9300 | 2.0800 | 18.1269 | 87.2100 | AID588849 |
| CAAX prenyl protease | Saccharomyces cerevisiae S288C | AC50 | 23.1000 | 1.0790 | 17.9906 | 68.9400 | AID488788 |
| DNA repair protein RAD52 homolog isoform a | Homo sapiens (human) | AC50 | 17.4300 | 0.1500 | 12.0662 | 35.2100 | AID652116 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||